Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aplindore

Drug Profile

Aplindore

Alternative Names: DAB 452; Palindore; SLS-006; WAY-DAB 452

Latest Information Update: 28 Sep 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer Ligand Pharmaceuticals; Wyeth
  • Class Antiparkinsonians; Antipsychotics; Indoles; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Parkinson's disease; Restless legs syndrome
  • Discontinued Schizophrenia

Most Recent Events

  • 25 Jan 2019 Seelos Therapeutics plans a pivotal registration studies for Parkinson’s disease in 2019
  • 22 Sep 2016 Aplindore sub-licensed to Seelos Therapeutics
  • 31 Dec 2011 Aplindore is available for licensing as of 31 Dec 2011. http://www.ligand.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top